NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

A randomized triple-blind placebo controlled trial of amoxicillin for treatment of acute bronchitis in HIV-1 infected and uninfected adults in Nairobi, Kenya.

Nduba V, Mwachari CW, Meier A, Park D, Cohen CR; International Conference on AIDS (15th : 2004 : Bangkok, Thailand).

Int Conf AIDS. 2004 Jul 11-16; 15: abstract no. B12139.

Kenya Medical Research Institute, Nairobi, Kenya

Background: Acute respiratory tract infection (RTI) is the most common presentation to outpatient clinics in HIV-1 infected and uninfected adults in sub-Saharan Africa, with antibiotics prescribed for 50% to 90% of cases. We performed a randomized placebo controlled trial to determine whether treatment with amoxicillin vs. placebo produced equivalent cure rates in an adult population with a high HIV-1 seroprevalence presenting to an outpatient clinic in Nairobi. Methods: Adults with an acute productive cough 14 days were screened; those with evidence of chronic bronchitis, asthma, postnasal drip, sinusitis, penicillin allergy, clinical evidence of lung disease and abnormal chest X-ray were excluded. Those meeting eligibility criteria were tested for HIV-1. Enrolled participants were randomized to receive amoxicillin 500 mg thrice daily for seven days or a matched placebo, and returned for follow-up after 3, 7 and 14 days. A scoring system that included clinical signs and symptoms, and laboratory findings was used at every visit to assess clinical severity; a 75% decline at two-weeks was the primary outcome. With a significance level of.05, 700 adults will provide 80% power to demonstrate equivalent cure rates in the two study arms. Results: Since January 2002, 2506 adults were screened and 587 (23%) were enrolled representing 84% of the total sample size. Among those enrolled, the average age was 30 (SD 9), and 353 (60%) were female. Overall, 128 (22%) were HIV-1 seropositive: 94 of 353 (27%) of women and 34 of 234 (15%) of men (p=.001). Recruitment and follow-up will continue through March 2004, with final analysis available by June 2004. Conclusion: As the first randomized placebo controlled trial of acute bronchitis in Africa and the first to include HIV-1 infected individuals, findings from this investigation will guide development of outpatient treatment guidelines for RTI in similar populations with high HIV-1 seroprevalence.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Acute Disease
  • Adult
  • Africa
  • Africa South of the Sahara
  • Amoxicillin
  • Anti-Bacterial Agents
  • Blindness
  • Bronchitis
  • Case-Control Studies
  • Clinical Trials as Topic
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • HIV Seropositivity
  • HIV-1
  • Humans
  • Kenya
  • Male
  • Penicillins
  • Placebos
  • Respiratory Tract Infections
  • Seroepidemiologic Studies
  • Sinusitis
  • drug therapy
  • therapy
Other ID:
  • GWAIDS0032648
UI: 102276862

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov